This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
Scientific Reports Open Access 19 February 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH . BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13: 588–595.
Caballero MD, Rubio V, Rifon J, Heras I, GarcÃa-Sanz R, Vázquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med 2013; 369: 1681–1690.
Martin N, Borchiellini D, Coso D, Gastaud L, Boscagli A, Saudes L et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma 2015; 56: 2379–2387.
Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010; 45: 1147–1153.
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.
Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ARA-C and dexamethasone (DHAP). Blood 1988; 71: 117–122.
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994..
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.
Blijlevens N, Schwenkglenks M, Bacon P, D’Addio A, Einsele H, Maertens J et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519–1525.
Batlle M, Morgades M, Vives S, Ferrà C, Oriol A, Sancho JM et al. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma. Eur J Haematol 2014; 93: 487–491.
Chen YB, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2015; 21: 1046–1053.
Czyz A, Lojko-Dankowska A, Dytfeld D, Nowicki A, Gil L, Matuszak M et al. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience. Med Oncol 2013; 30: 611–619.
Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Group d’Etude des Lymphomes de l’Adulte. Blood 2013; 121: 48–53.
Acknowledgements
The authors thank AIL Ascoli Piceno ‘Alessandro Troiani’ ONLUS for supporting this study and Federica Liberi for the English revision of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Galieni, P., Troiani, E., Bigazzi, C. et al. Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 53, 91–93 (2018). https://doi.org/10.1038/bmt.2017.206
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.206
This article is cited by
-
Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL
Bone Marrow Transplantation (2022)
-
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin’s lymphoma patients
Scientific Reports (2021)